Path AI: Michael Montalto
Path AI has appointed Michael Montalto its chief science officer. He joins the company from Bristol-Myers Squibb where he was vice president and head of translational sciences, translational medicine. Before that, he was cofounder of and an executive at Omnyx, a joint venture of GE Healthcare and the University of Pittsburgh Medical Center that commercialized diagnostic pathology imaging and software products. Montalto was the molecular imaging and diagnostics advanced technology leader at GE before that.